Project Grant R01AI182314
Award Date
7/25/25
Completion Date
6/30/29
Dollars Obligated
$3.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $354,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Case Western Reserve University (CWRU) for the development of a cost-effective, user-friendly point-of-care (POC) diagnostic tool for HIV and hepatitis B virus (HBV) co-infection. The project aims to create a microchip-based "CamoChip" technology that integrates serological and molecular tests for HIV and HBV into...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to reduce overtreatment and prevent emerging antibiotic resistance. In Phase I, the company will develop viability PCR (V-PCR) assays for Chlamydia trachomatis and Neisseria...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The platform will isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes, enabling clinicians to quickly determine appropriate targeted...
This $198,630 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize porin mutations and expand the capabilities of the BADLOCK CRISPR-based diagnostic test. The goal is to improve diagnostic capacity for antibiotic-resistant bacterial infections, especially carbapenem-resistant Enterobacterales, in resource-limited settings. Key activities include...
This Project Grant award of $305,000.00 from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The goal is to create a microfluidic-based platform that can provide actionable AST results within 6-9 hours, compared to the current 3-5 day turnaround, to help physicians prescribe the optimal antibiotic dosage sooner. This will reduce...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $2,082,247 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an economical, rapid molecular diagnostic system for detecting hepatitis C virus (HCV) and HIV from whole blood samples. The research aims to overcome barriers to low-cost implementation of molecular diagnostics for RNA viruses by creating novel chemistries and microfluidics to enable minimally...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Resonantia Diagnostics, Inc. to develop a rapid diagnostic platform for identifying pathogens and determining antimicrobial susceptibility within 60 minutes. The project aims to advance an acoustic sensor-based technology that can accurately detect pathogens at low concentrations and test their susceptibility to a diverse range of...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
This $195,480 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and pilot implementation of a low-cost, point-of-care diagnostic assay to detect Neisseria gonorrhoeae infection and molecular markers of antimicrobial resistance in resource-limited settings. The award recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,244 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Sherlock Biosciences, Inc. to develop a power-free, molecular diagnostic device that can detect Chlamydia trachomatis and Neisseria gonorrhoeae from self-collected vaginal swabs. The project aims to create an accurate, easy-to-use, and accessible at-home test for these sexually transmitted infections without requiring...